Institutional members access full text with Ovid®

Share this article on:

Results of the STAR*D Study: Implications for Clinicians and Drug Developers

Preskorn, Sheldon H. MD* †

Journal of Psychiatric Practice®: January 2009 - Volume 15 - Issue 1 - p 45-49
doi: 10.1097/01.pra.0000344918.51404.1e
Columns: Psychopharmacology

*Department of Psychiatry, University of Kansas School of Medicine-Wichita

Clinical Research Institute, Wichita, Kansas

He has more than 30 years of drug development research experience at all levels (ie, preclinical through Phase IV) and has been a principal investigator on over 250 clinical trials including every antidepressant marketed in the United States over the last 25 years. Dr. Preskorn maintains a website at 〈www.preskorn.com〉 where readers can access previous columns and other publications.

Disclosure statement: Dr. Preskorn, as chief executive officer of the Clinical Research Institute, Wichita, KS, and, in many cases, as principal investigator, has received grants from the following entities: AstraZeneca, Biovail, Boehringer-Ingelhaim, Bristol-Myers Squibb, Comentis, Cyberonics, Eisai, EnViVo, GlaxoSmithKline, Merck, Memory, Organon, Otsuka, Pfizer, Sepracor, Somerset, Wyeth, and the National Institute of Mental Health. He has served as a consultant, on the advisory board, and/or as a speaker for the following: Biovail, Bristol-Myers Squibb, Comentis, Covedien, Cyberonics, Eli Lilly, EnViVo, Evotec, Fabre-Kramer, Jazz, Memory, Organon, Pfizer, Somerset, Transcept, and Wyeth.

© 2009 Lippincott Williams & Wilkins, Inc.